Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Eli Lilly's Weight-Loss Empire Keeps Expanding As Mounjaro, Zepbound Generate Nearly $15 Billion

Eli Lilly

Eli Lilly and Co. (NYSE:LLY) stock traded higher Wednesday after the drugmaker reported second-quarter results that topped Wall Street expectations and raised its full-year revenue outlook, driven by continued demand for its diabetes and obesity treatments.

The company’s obesity and diabetes franchise remained its biggest growth engine in the second quarter, with blockbuster GLP-1 drugs Mounjaro and Zepbound generating a combined $14.9 billion in revenue.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.